ONCOLOGY · PROSTATE CANCER
ZEN003694 metastatic prostate cancer study
A randomized Phase 2b study of ZEN003694 with enzalutamide.
Study overview
This randomized Phase 2b study is evaluating ZEN003694 in combination with enzalutamide compared with enzalutamide alone in people with metastatic castration-resistant prostate cancer. Metastatic means cancer has spread beyond the prostate. Castration-resistant means the disease continues to progress despite treatment that lowers or blocks testosterone. The protocol defines required disease findings, prior treatments, laboratory results, and other eligibility criteria.
What the research examines
Randomized studies assign participants to a study group according to the protocol. Researchers compare outcomes between the combination group and the enzalutamide-only group while monitoring safety and tolerability. Procedures may include examinations, laboratory tests, imaging, prostate-specific antigen testing, tumor assessments, and side-effect monitoring. ZEN003694 is investigational, so its benefits and risks are not fully established. Enzalutamide also has known risks that the research team reviews during informed consent.
Asking about participation
Eligibility may depend on prostate cancer history, metastatic disease, prior therapy, current medications, general health, and protocol-defined test results. Study availability can change as enrollment progresses. Screening does not guarantee enrollment, and contacting California Research Institute does not obligate you to participate.
Participation is voluntary. The research team explains study groups, required visits, procedures, foreseeable risks, alternatives, privacy protections, and participant rights. You may discuss the study with your oncologist, family, or another trusted adviser before deciding.
For current information, call (323) 660-6200 or email trials@caresinst.org. Please do not email medical records, insurance details, or sensitive health information. This page is educational and does not replace medical advice.
The coordinator can explain current availability and the initial screening process.